INVEST: INternational VErapamil SR Trandolapril STudy


MUTLU H.

Diğer, ss.30, 2005

  • Basım Tarihi: 2005
  • Sayfa Sayıları: ss.30

Özet

This study has been completed.
Sponsor:
Collaborator:
Abbott
Information provided by (Responsible Party):
University of Florida
ClinicalTrials.gov Identifier:
NCT00133692
First received: August 22, 2005
Last updated: September 16, 2011
Last verified: August 2010

  Purpose

Because blood pressure affects the heart, blood vessels, kidneys, and the entire body, it is important to keep it as normal as possible. There are several different ways to control blood pressure and to prevent or limit the development of heart disease due to high blood pressure. The purpose of this study is to compare two treatments to see how well they work and the difference in their side effects. One treatment includes the use of a calcium antagonist drug (Isoptin sustained release [SR] or Verapamil SR). The other treatment excludes the calcium antagonist and may include a non-calcium antagonist drug called a beta blocker (Tenormin or Atenolol). Both treatments may also include medication called angiotensin converting enzyme (ACE) inhibitors and water pills. None of the drugs in this study are experimental, they are all approved by the Food and Drug Administration (FDA).


Condition Intervention Phase
Hypertension
Coronary Artery Disease
Drug: Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ)
Drug: Atenolol/HCTZ/Trandolapril
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: INternational VErapamil SR Trandolapril STudy

Resource links provided by NLM:


Further study details as provided by University of Florida:

Primary Outcome Measures:
  • First occurrence of death or nonfatal myocardial infarction (MI) or nonfatal stroke

Secondary Outcome Measures:
  • Death
  • Nonfatal MI
  • Nonfatal stroke
  • Newly diagnosed diabetes
  • BP control
  • Cancer
  • Gastrointestinal (GI) bleeding
  • Alzheimer's Disease
  • Parkinson's Disease
  • Cardiovascular (CV) hospitalizations
  • Quality of life
  • Compliance

Estimated Enrollment: 22000
Study Start Date: September 1997
Estimated Study Completion Date: February 2003
Detailed Description:

INVEST is an investigator initiated international, prospective, randomized study comparing two pharmacotherapy strategies to control hypertension in ambulatory patients with coronary artery disease (CAD). One strategy, the calcium antagonist care strategy, centers on a calcium antagonist (verapamil SR) followed by addition of an ACE inhibitor (trandolapril) and then diuretic (hydrochlorothiazide) as needed to achieve target blood pressures (BP). The other strategy, the non-calcium antagonist care strategy, uses a beta-blocker (atenolol) followed by addition of low-dose diuretic and then an ACE inhibitor (trandolapril) as needed to reach target BP. In either strategy additional drugs can be added provided the calcium antagonist is retained in the calcium antagonist care strategy and calcium antagonists are omitted in the non-calcium antagonist care strategy.

The study is organized into 15 international regions with about 1,500 study investigators randomizing approximately 22,000 patients who will be treated for at least two years. The primary response variable is the occurrence of adverse outcome, defined as any of the following events: all cause mortality, nonfatal MI or nonfatal stroke. A number of secondary response variables, including newly diagnosed diabetes will also be evaluated.

The primary objective of this trial is to examine the hypothesis that the risk for adverse outcomes (all cause mortality, nonfatal MI or nonfatal stroke) in hypertensive patients with CAD is at least equivalent during treatment of hypertension with a calcium antagonist strategy when compared with a non-calcium antagonist strategy.